Last reviewed · How we verify
NCT05004961
The Performance of Multi-tracer Multimodality PET in Lymphoma
trial in Positron-Emission Tomography in 200 participants. Status unknown.
15 August 2023
Quick facts
| Lead sponsor | Peking University Cancer Hospital & Institute |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 September 2019 |
| Primary completion | 15 August 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Conditions studied
- Positron-Emission Tomography — all drugs for Positron-Emission Tomography →
Sponsor
Peking University Cancer Hospital & Institute
Who can join
Adults 15 to 80, any sex, with Positron-Emission Tomography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigating the performance of Multi-tracer Multimodality PET in lymphoma
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.
van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, et al · · 2022 · cited 21× · PMID 35733858 · DOI 10.3389/fmed.2022.902155 -
Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.
Wu Y, Wang X, Sun X, Gao X, et al · · 2025 · cited 7× · PMID 41049753 · DOI 10.1016/j.apsb.2025.07.009 -
Recent Updates of PET in Lymphoma: FDG and Beyond.
Kim SY, Chung HW, So Y, Lee MH, et al · · 2024 · cited 2× · PMID 39595051 · DOI 10.3390/biomedicines12112485 -
Diagnostic performance of integrated whole-body <sup>18</sup>F-FDG PET/MRI for detecting bone marrow involvement in indolent lymphoma: Comparison with <sup>18</sup>F-FDG PET or MRI alone.
Chen X, Yuan T, Wei M, Yu B, et al · · 2023 · cited 2× · PMID 36994205 · DOI 10.3389/fonc.2023.1136687
Verify or expand the search:
- PubMed search for NCT05004961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Positron-Emission Tomography
Currently open trials in the same condition.
- NCT06387381 — 68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease · EARLY_PHASE1 · recruiting
- NCT06203574 — Clinical Study of TROP-2 PET/CT for Noninvasive Diagnosis of Solid Tumors · NA · recruiting
- NCT05873777 — 68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG · NA · recruiting
- NCT05610098 — Gene Expression Profiles in Spinal Tuberculosis. · recruiting
- NCT04416165 — Comparison of FDG and FAPI in Patients With Various Types of Cancer · NA · recruiting
Other Peking University Cancer Hospital & Institute trials
Trials by the same sponsor.
- NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
- NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
- NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05004961 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
- Last refreshed: 3 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05004961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing